IDT Appoints Experienced Executive William Conkling as Independent Director and Audit Committee Chair
IDT sits 20% above its 52-week low of $45.72.
Summary
IDT Corporation appointed William Conkling, an experienced executive, as an independent director and Chairman of the Audit Committee, enhancing corporate governance.
Key Events · Executive and Board Changes · IDT
-
Director Resignation
Irwin Katsof resigned from the Board and its committees on June 9, 2026. The company stated this was not due to any disagreement regarding operations, policies, or practices.
-
New Independent Director Appointed
William Conkling was appointed to the Board on June 9, 2026. He is determined to be 'independent' in accordance with NYSE listing standards and SEC rules.
-
Key Committee Roles
Mr. Conkling is expected to serve as Chairman of the Audit Committee and be the Audit Committee Financial Expert, as well as a member of the Compensation Committee and Corporate Governance Committee.
-
Extensive Executive Experience
Mr. Conkling brings experience as Chief Commercial Officer of Protara Therapeutics Inc. and former CEO of Rafael Holdings, Inc., with prior leadership roles at Immunomedics Inc. and Novartis.
Analysis · IDT · Technology
IDT Corporation has strengthened its board governance by appointing William Conkling, an experienced executive with a strong background in commercial and financial oversight, as an independent director. His role as Chairman of the Audit Committee and Audit Committee Financial Expert is a significant enhancement to the company's financial stewardship and oversight, which is a positive development for investors.
At the time of this filing, IDT was trading at $55.04 on NYSE in the Technology sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $45.72 to $71.12. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.